The ARL6IP1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, designed to disrupt the ARL6IP1 gene. This product provides a heterogeneous pool of gene-edited cells, offering a loss-of-function model without single-cell cloning. CRISPR/Cas9-mediated gene disruption introduces targeted mutations, enabling functional studies of ARL6IP1 in an immortalized human epithelial background. The polyclonal nature preserves population-level knockout consistency while reflecting diverse editing outcomes, making it suitable for experiments where clonal heterogeneity is acceptable.
HeLa cells, an HPV18-positive cervical adenocarcinoma epithelial line, are widely utilized in research due to their robust proliferation, genetic stability, and relevance to cancer biology and signal transduction. The cell line??s dysregulated apoptotic and ER stress pathways, partly attributable to viral oncoprotein expression, provide a physiologically pertinent system for exploring the stress-modulatory roles of ARL6IP1. HeLa??s extensive characterization and experimental tractability facilitate the integration of this knockout model into diverse biochemical and cell-based assays.
ARL6IP1 encodes an ER-localized protein that critically regulates endoplasmic reticulum morphology and vesicular trafficking through direct interaction with ATL1, a GTPase essential for ER network formation. Additionally, ARL6IP1 exerts anti-apoptotic effects by sequestering Bcl-2 at the ER membrane, preventing mitochondrial cytochrome c release and suppressing caspase-9 activation. Within the IRE1??-mediated ER stress response pathway, accumulation of unfolded proteins triggers IRE1?? autophosphorylation, leading to XBP1 mRNA splicing and expression of the active transcription factor XBP1s, which transcriptionally upregulates ARL6IP1. ARL6IP1 also forms complexes with RTN4 to maintain tubular ER architecture, directly coupling structural homeostasis to cell survival. Pharmacological ER stressors such as tunicamycin and thapsigargin are commonly used to dissect this signaling network.
In the HeLa cellular context, deletion of ARL6IP1 is anticipated to compromise ER homeostasis and lower the threshold for apoptosis, providing a model to investigate how ER dysfunction contributes to pathologies such as hereditary spastic paraplegia and neurodegenerative disorders. The cancer background also permits examination of ARL6IP1??s role in tumor cell viability and adaptive stress responses, given its overexpression in certain malignancies. This knockout system thus serves as a versatile platform for connecting basic cell biology to disease mechanisms.
Researchers can employ this polyclonal population in a range of assays, including western blotting and RT-qPCR to verify knockout efficiency, immunofluorescence microscopy to visualize ER structural changes, and apoptosis assays such as TUNEL staining or caspase activity measurements. Co-immunoprecipitation enables analysis of ARL6IP1 interactions with ATL1 and Bcl-2, while flow cytometry and MTT assays provide quantitative readouts of stress sensitivity. Applications encompass ER stress research, apoptosis signaling, intracellular trafficking, and disease modeling. For further technical information, please contact Ascent Research.
